A detailed history of Empirical Financial Services, LLC D.B.A. Empirical Wealth Management transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Empirical Financial Services, LLC D.B.A. Empirical Wealth Management holds 1,251 shares of VRTX stock, worth $593,687. This represents 0.02% of its overall portfolio holdings.

Number of Shares
1,251
Previous 1,048 19.37%
Holding current value
$593,687
Previous $426,000 22.54%
% of portfolio
0.02%
Previous 0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 06, 2024

BUY
$407.69 - $446.08 $82,761 - $90,554
203 Added 19.37%
1,251 $522,000
Q4 2023

Feb 06, 2024

BUY
$343.0 - $410.68 $23,324 - $27,926
68 Added 6.94%
1,048 $426,000
Q3 2023

Nov 02, 2023

SELL
$338.18 - $362.46 $7,101 - $7,611
-21 Reduced 2.1%
980 $340,000
Q2 2023

Aug 11, 2023

SELL
$314.42 - $351.91 $108,474 - $121,408
-345 Reduced 25.63%
1,001 $352,000
Q4 2022

Feb 07, 2023

SELL
$285.76 - $321.48 $11,144 - $12,537
-39 Reduced 2.82%
1,346 $388,000
Q3 2022

Nov 02, 2022

SELL
$273.83 - $305.53 $107,615 - $120,073
-393 Reduced 22.1%
1,385 $401,000
Q2 2022

Aug 02, 2022

SELL
$234.96 - $292.55 $72,132 - $89,812
-307 Reduced 14.72%
1,778 $501,000
Q1 2022

May 13, 2022

SELL
$221.42 - $260.97 $401,877 - $473,660
-1,815 Reduced 46.54%
2,085 $544,000
Q4 2021

Feb 14, 2022

SELL
$177.01 - $223.45 $366,764 - $462,988
-2,072 Reduced 34.7%
3,900 $856,000
Q3 2021

Nov 02, 2021

BUY
$181.39 - $202.99 $368,403 - $412,272
2,031 Added 51.54%
5,972 $1.08 Million
Q2 2021

Aug 12, 2021

BUY
$187.49 - $221.1 $286,672 - $338,061
1,529 Added 63.39%
3,941 $795,000
Q1 2021

May 17, 2021

BUY
$207.02 - $241.31 $499,332 - $582,039
2,412 New
2,412 $518,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $122B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Empirical Financial Services, LLC D.B.A. Empirical Wealth Management Portfolio

Follow Empirical Financial Services, LLC D.B.A. Empirical Wealth Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Empirical Financial Services, LLC D.B.A. Empirical Wealth Management, based on Form 13F filings with the SEC.

News

Stay updated on Empirical Financial Services, LLC D.B.A. Empirical Wealth Management with notifications on news.